Compositions and methods related to k180 dimethylated h1.0 protein
AssigneeAelan Cell Technologies, Inc.
InventorsVictoria LUNYAK, James Robert TOLLERVEY
Life of this patent
Estimating the term…
Loading patent…
AssigneeAelan Cell Technologies, Inc.
InventorsVictoria LUNYAK, James Robert TOLLERVEY
Estimating the term…
Provided herein are H1.0K180me2 antibodies, H1.0K180me2 proteins, and H1.0K180me2 peptides and methods of use for diagnostics and therapeutics. These H1.0K180me2 antibodies, H1.0K180me2 proteins, and H1.0K180me2 peptides may be used in the treatment of methylated H1.0-related diseases or conditions in an individual. These H1.0K180me2 antibodies, H1.0K180me2 proteins, and H1.0K180me2 peptides may also be used for the detection and quantification of a histone H1.0 protein or fragment thereof, comprising a dimethylated lysine at lysine residue 180 (H1.0K180me2); such compositions and methods are useful for detecting replicative senescence, DNA damage, genotoxic stress, radiation exposure, Alzheimer's disease, are useful for monitoring therapeutic regimens, patient stratification, drug screening, and may serve as a marker of biological aging in a system.
-15. (canceled)
A synthetic histone H1.0 peptide comprising a dimethylated lysine residue, wherein the dimethylated lysine residue corresponds to K180 of a human histone H1.0.
-21. (canceled)
-25. (canceled)
-182. (canceled)
A diagnostic kit comprising the peptide of claim 1.
A transdermal patch for measuring a concentration of a hypodermal target molecule, comprising:
A portable unit for determining whether an individual has been exposed to radiation or a DNA-damaging agent, comprising:
A test strip suitable for a lateral flow assay of an analyte, comprising a sample receiving zone, wherein the sample receiving zone comprises the peptide of claim 1.
A pharmaceutical composition comprising the peptide of claim 1 and a pharmaceutically acceptable excipient.
Dependencies are inferred from the claim text.